STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

BCPC Form 4: Officer awarded 2,500 restricted shares at $0

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Balchem Corp (BCPC) reported that its SVP and Chief R&D Officer acquired 2,500 shares of common stock on 10/20/2025 via a restricted stock grant at $0 per share. Following the transaction, the reporting person beneficially owns 2,500 shares, held directly.

The award vests ratably over three years—25% on the first anniversary, 25% on the second, and 50% on the third—subject to transfer restrictions under a Restricted Stock Grant Agreement.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Graham George

(Last) (First) (Middle)
C/O BALCHEM CORPORATION
5 PARAGON DRIVE

(Street)
MONTVALE NJ 07645

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BALCHEM CORP [ BCPC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP and Chief R&D Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/20/2025 A 2,500(1) A $0 2,500 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Ownership of restricted stock vests in Reporting Person ratably over a 3 year period (25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 50% on the third anniversary of the grant date), subject to restrictions on transfer in accordance with the provisions of a Restricted Stock Grant Agreement between the Issuer and the Reporting Person.
/s/ Travis Larsen, Attorney in Fact for George Graham 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Balchem (BCPC) disclose in this Form 4?

An officer received a restricted stock grant of 2,500 shares on 10/20/2025 at $0 per share.

Who is the reporting person in the BCPC filing?

The SVP and Chief R&D Officer of Balchem Corporation.

How does the 2,500-share award vest for BCPC?

It vests 25% on the first anniversary, 25% on the second, and 50% on the third.

What is the ownership form after the transaction for BCPC?

The 2,500 shares are held directly by the reporting person.

Is the BCPC grant subject to restrictions?

Yes, it has transfer restrictions under a Restricted Stock Grant Agreement.

What transaction code appears in the BCPC Form 4?

Transaction code A, indicating an acquisition (restricted stock award).
Balchem Corp

NASDAQ:BCPC

BCPC Rankings

BCPC Latest News

BCPC Latest SEC Filings

BCPC Stock Data

4.89B
32.21M
0.37%
90.95%
1.44%
Specialty Chemicals
Chemicals & Allied Products
Link
United States
MONTVALE